NEW YORK – Despite recording $1 billion in revenues for the first time in its history, Quidel on Thursday also reported a hiccup in its plans to submit an over-the-counter viral antigen test for regulatory authorization. The firm provided details on two anticipated product launches as well.
On a conference call reviewing its fourth quarter and full-year 2020 financial results, company executives also admonished investors to ignore unfounded M&A rumors.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.